Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia

Arthur J. Moss, W. Jackson Hall, David S. Cannom, James P. Daubert, Steven L. Higgins, Helmut Klein, Joseph H. Levine, Sanjeev Saksena, Albert L. Waldo, David Wilber, Mary W. Brown, Moonseong Heo

Research output: Contribution to journalArticle

3273 Citations (Scopus)

Abstract

Background: Unsustained ventricular tachycardia in patients with previous myocardial infarction and left ventricular dysfunction is associated with a two-year mortality rate of about 30 percent. We studied, whether prophylactic therapy with an implanted cardioverter-defibrillator, as compared with conventional medical therapy, would improve survival in this high-risk group of patients. Methods: Over the course of five years, 196 patients in New York Heart Association functional class I, II, or III with prior myocardial infarction; a left ventricular ejection fraction ≤0.35; a documented episode of asymptomatic unsustained ventricular tachycardia; and inducible, nonsuppressible ventricular tachyarrhythmia on electrophysiologic study were randomly assigned to receive an implanted defibrillator (n=95) or conventional medical therapy (n= 101). We used a two-sided sequential design with death from any cause as the end point. Results: The base-line characteristics of the two treatment groups were similar. During an average follow-up of 27 months, there were 15 deaths in the defibrillator group (11 from cardiac causes) and 39 deaths in the conventional-therapy group (27 from cardiac causes) (hazard ratio for overall mortality, 0.46; 95 percent confidence interval, 0.26 to 0.82; P=0.009). There was no evidence that amiodarone, beta-blockers, or any other antiarrhythmic therapy had a significant influence on the observed hazard ratio. Conclusions: In patients with a prior myocardial infarction who are at high risk for ventricular tachyarrhythmia, prophylactic therapy with an implanted defibrillator leads to improved survival as compared with conventional medical therapy.

Original languageEnglish (US)
Pages (from-to)1933-1940
Number of pages8
JournalNew England Journal of Medicine
Volume335
Issue number26
DOIs
StatePublished - Dec 26 1996
Externally publishedYes

Fingerprint

Defibrillators
Coronary Disease
Cardiac Arrhythmias
Survival
Myocardial Infarction
Ventricular Tachycardia
Tachycardia
Therapeutics
Cause of Death
Amiodarone
Mortality
Left Ventricular Dysfunction
Group Psychotherapy
Stroke Volume
Confidence Intervals

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. / Moss, Arthur J.; Jackson Hall, W.; Cannom, David S.; Daubert, James P.; Higgins, Steven L.; Klein, Helmut; Levine, Joseph H.; Saksena, Sanjeev; Waldo, Albert L.; Wilber, David; Brown, Mary W.; Heo, Moonseong.

In: New England Journal of Medicine, Vol. 335, No. 26, 26.12.1996, p. 1933-1940.

Research output: Contribution to journalArticle

Moss, AJ, Jackson Hall, W, Cannom, DS, Daubert, JP, Higgins, SL, Klein, H, Levine, JH, Saksena, S, Waldo, AL, Wilber, D, Brown, MW & Heo, M 1996, 'Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia', New England Journal of Medicine, vol. 335, no. 26, pp. 1933-1940. https://doi.org/10.1056/NEJM199612263352601
Moss, Arthur J. ; Jackson Hall, W. ; Cannom, David S. ; Daubert, James P. ; Higgins, Steven L. ; Klein, Helmut ; Levine, Joseph H. ; Saksena, Sanjeev ; Waldo, Albert L. ; Wilber, David ; Brown, Mary W. ; Heo, Moonseong. / Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. In: New England Journal of Medicine. 1996 ; Vol. 335, No. 26. pp. 1933-1940.
@article{a070107c95fc47fe8030e965bfe7c34e,
title = "Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia",
abstract = "Background: Unsustained ventricular tachycardia in patients with previous myocardial infarction and left ventricular dysfunction is associated with a two-year mortality rate of about 30 percent. We studied, whether prophylactic therapy with an implanted cardioverter-defibrillator, as compared with conventional medical therapy, would improve survival in this high-risk group of patients. Methods: Over the course of five years, 196 patients in New York Heart Association functional class I, II, or III with prior myocardial infarction; a left ventricular ejection fraction ≤0.35; a documented episode of asymptomatic unsustained ventricular tachycardia; and inducible, nonsuppressible ventricular tachyarrhythmia on electrophysiologic study were randomly assigned to receive an implanted defibrillator (n=95) or conventional medical therapy (n= 101). We used a two-sided sequential design with death from any cause as the end point. Results: The base-line characteristics of the two treatment groups were similar. During an average follow-up of 27 months, there were 15 deaths in the defibrillator group (11 from cardiac causes) and 39 deaths in the conventional-therapy group (27 from cardiac causes) (hazard ratio for overall mortality, 0.46; 95 percent confidence interval, 0.26 to 0.82; P=0.009). There was no evidence that amiodarone, beta-blockers, or any other antiarrhythmic therapy had a significant influence on the observed hazard ratio. Conclusions: In patients with a prior myocardial infarction who are at high risk for ventricular tachyarrhythmia, prophylactic therapy with an implanted defibrillator leads to improved survival as compared with conventional medical therapy.",
author = "Moss, {Arthur J.} and {Jackson Hall}, W. and Cannom, {David S.} and Daubert, {James P.} and Higgins, {Steven L.} and Helmut Klein and Levine, {Joseph H.} and Sanjeev Saksena and Waldo, {Albert L.} and David Wilber and Brown, {Mary W.} and Moonseong Heo",
year = "1996",
month = "12",
day = "26",
doi = "10.1056/NEJM199612263352601",
language = "English (US)",
volume = "335",
pages = "1933--1940",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "26",

}

TY - JOUR

T1 - Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia

AU - Moss, Arthur J.

AU - Jackson Hall, W.

AU - Cannom, David S.

AU - Daubert, James P.

AU - Higgins, Steven L.

AU - Klein, Helmut

AU - Levine, Joseph H.

AU - Saksena, Sanjeev

AU - Waldo, Albert L.

AU - Wilber, David

AU - Brown, Mary W.

AU - Heo, Moonseong

PY - 1996/12/26

Y1 - 1996/12/26

N2 - Background: Unsustained ventricular tachycardia in patients with previous myocardial infarction and left ventricular dysfunction is associated with a two-year mortality rate of about 30 percent. We studied, whether prophylactic therapy with an implanted cardioverter-defibrillator, as compared with conventional medical therapy, would improve survival in this high-risk group of patients. Methods: Over the course of five years, 196 patients in New York Heart Association functional class I, II, or III with prior myocardial infarction; a left ventricular ejection fraction ≤0.35; a documented episode of asymptomatic unsustained ventricular tachycardia; and inducible, nonsuppressible ventricular tachyarrhythmia on electrophysiologic study were randomly assigned to receive an implanted defibrillator (n=95) or conventional medical therapy (n= 101). We used a two-sided sequential design with death from any cause as the end point. Results: The base-line characteristics of the two treatment groups were similar. During an average follow-up of 27 months, there were 15 deaths in the defibrillator group (11 from cardiac causes) and 39 deaths in the conventional-therapy group (27 from cardiac causes) (hazard ratio for overall mortality, 0.46; 95 percent confidence interval, 0.26 to 0.82; P=0.009). There was no evidence that amiodarone, beta-blockers, or any other antiarrhythmic therapy had a significant influence on the observed hazard ratio. Conclusions: In patients with a prior myocardial infarction who are at high risk for ventricular tachyarrhythmia, prophylactic therapy with an implanted defibrillator leads to improved survival as compared with conventional medical therapy.

AB - Background: Unsustained ventricular tachycardia in patients with previous myocardial infarction and left ventricular dysfunction is associated with a two-year mortality rate of about 30 percent. We studied, whether prophylactic therapy with an implanted cardioverter-defibrillator, as compared with conventional medical therapy, would improve survival in this high-risk group of patients. Methods: Over the course of five years, 196 patients in New York Heart Association functional class I, II, or III with prior myocardial infarction; a left ventricular ejection fraction ≤0.35; a documented episode of asymptomatic unsustained ventricular tachycardia; and inducible, nonsuppressible ventricular tachyarrhythmia on electrophysiologic study were randomly assigned to receive an implanted defibrillator (n=95) or conventional medical therapy (n= 101). We used a two-sided sequential design with death from any cause as the end point. Results: The base-line characteristics of the two treatment groups were similar. During an average follow-up of 27 months, there were 15 deaths in the defibrillator group (11 from cardiac causes) and 39 deaths in the conventional-therapy group (27 from cardiac causes) (hazard ratio for overall mortality, 0.46; 95 percent confidence interval, 0.26 to 0.82; P=0.009). There was no evidence that amiodarone, beta-blockers, or any other antiarrhythmic therapy had a significant influence on the observed hazard ratio. Conclusions: In patients with a prior myocardial infarction who are at high risk for ventricular tachyarrhythmia, prophylactic therapy with an implanted defibrillator leads to improved survival as compared with conventional medical therapy.

UR - http://www.scopus.com/inward/record.url?scp=0006918490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0006918490&partnerID=8YFLogxK

U2 - 10.1056/NEJM199612263352601

DO - 10.1056/NEJM199612263352601

M3 - Article

VL - 335

SP - 1933

EP - 1940

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 26

ER -